Company / Free Cash Flow
Edwards Lifesciences Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$1.3B
FY2025
5-year range
$289.9M / $1.4B
FY2021-FY2025
Trend
+360.5%
vs FY2024
Sector context
#22 of 151
Health Care
What the data says
Free Cash Flow changed +361% YoY in FY2025, a notable deviation from the 9-year average annual change of +51%.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +15.6%. Top quartile in the Health Care sector.
Declined from $1.4B to $1.3B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +11.1%
- 5-Year CAGR
- +15.6%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 151This company $1.3B Sector average $779.8M
▼
+71.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +15.6%, indicating consistent growth.
- In FY2025, free cash flow increased 360.5% year-over-year.
- Ranks #22 out of 151 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +360.5% |
| FY2024 | $289.9M | -79.4% |
| FY2023 | $1.4B | +44.4% |
| FY2022 | $973.6M | -30.8% |
| FY2021 | $1.4B | +117.3% |
| FY2020 | $647.3M | -30.3% |
| FY2019 | $928.5M | +35.0% |
| FY2018 | $688.0M | -17.4% |
| FY2017 | $832.6M | +57.6% |
| FY2016 | $528.3M | +18.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026